Sakar Healthcare Q2 FY27 Revenue Surges 52% to ₹874 Cr, EBITDA More Than Doubles
Sakar Healthcare reported a 52% year-on-year revenue growth to ₹874.16 crore for Q2 FY27. EBITDA more than doubled to ₹243.45 crore, with margins improving to 28%. Profit after tax surged 149% to ₹113.07 crore. The company executed 69 oncology product contracts and secured 22 marketing authorizations globally.
The strong financial performance and positive operational developments are likely to have a significant positive impact on investor sentiment and the company's stock.
The company reported significantly strong financial results with substantial year-on-year growth in revenue, EBITDA, and profit after tax. Operational highlights also indicate positive momentum in product development and market penetration.
Sakar Healthcare Limited announced a significant financial performance for the quarter ended September 30, 2026. Revenue from operations for Q2 FY27 grew by 52% year-on-year to ₹8,741.61 lakhs (₹874.16 crore), while the first half of FY27 saw a 45% increase in revenue to ₹16,038.86 lakhs (₹1,603.89 crore).
The company's EBITDA more than doubled in Q2 FY27, rising by 114% to ₹2,434.53 lakhs (₹243.45 crore), with the EBITDA margin improving to 28% from 20% in the same period last year. For H1 FY27, EBITDA increased by 90% to ₹4,559.42 lakhs (₹455.94 crore), with margins expanding to 28% from 22%.
Profit after tax demonstrated strong growth, escalating by 149% to ₹1,130.69 lakhs (₹113.07 crore) in Q2 FY27 and by 134% to ₹2,159.18 lakhs (₹215.92 crore) in H1 FY27. This improvement is attributed to a stronger business mix, operating leverage, and the increasing contribution of the oncology business.
Operationally, Sakar Healthcare executed 69 oncology product contracts and is in discussions for an additional 45 opportunities internationally. The company has shared 351 oncology dossiers globally, with 191 submissions and 22 marketing authorizations granted, including approvals in Europe, UK, Latin America, Myanmar, and Canada. The CDMO business is also gaining momentum with 33 technology transfer projects underway. The company has developed 21 oncology APIs in-house, with eight products already commercialized.
What to do with a filing like this
Sakar Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sakar Healthcare Limited. Read the original for the full detail.